Tamtam Try Tamtam free
Withings logo

Withings account plan

Home Health Monitoring Devices

At a glance

Withings is a French connected-health company selling medical-grade devices and remote monitoring; profitable in FY2025 with a team of 400.

Withings, founded by Eric Carreel and based in France, makes clinically validated connected devices (scales, watches, blood pressure monitors, sleep analysers) for consumers and runs a B2B remote patient monitoring business for health programs, hospital networks, insurers and clinical research organisations in the US, UK and Europe. It reached full-year profitability in 2025, eight years after Carreel bought the company back from Nokia in 2018; it does not disclose absolute revenue, but says global revenue grew approximately 90% since 2018. 66% of 2025 revenue came from cleared medical devices, and 3.6 million of its 15 million active users are classified as medical users. The company has raised €61M / $71M since 2019 and has a global team of 400.

Business units

Strategic priorities

Obesity and GLP-1 programs as the B2B spearhead
500,000+ patients are enrolled in obesity care programs using Withings devices; named partners include Amba, Vitality, MedStar Health, Calibrate and 9amHealth, and a partnership with Novo Nordisk was announced in 2026.
Expand from weight loss to cardiometabolic care
Withings sees its best GLP-1 partners becoming cardiometabolic health programs, routing patients to hypertension or heart failure pathways, and plans to deploy risk scores, hypertension among them.
Risk scores built from longitudinal measurement
The stated strategy runs in three steps: be the champion of longitudinal measurement, build health scores such as a glucose resilience score for diabetes risk, then accompany patients between the medical system and daily life.
Grow recurring revenue through Withings+
The Withings+ subscription nearly doubled its revenue in 2025 and is the bridge that moves users from consumer to patient.
Position for AI-led remote monitoring in the US
Withings built a care team with medical doctors (Withings Medical) for the CMS ACCESS model for over-65 patients, and expects AI-analysed remote monitoring to spread to private US insurers and Europe.

Latest results

Withings announced on 6 May 2026 that it reached full-year profitability in 2025, without publishing revenue, margin or net income. Global revenue has grown approximately 90% since 2018, Withings+ revenue nearly doubled in 2025, and the UK made up 6% of global revenue. Devices recorded over 1 billion health measurements in 2025, 360 million of them clinical or medical grade. By October 2026 the B2B division said it was monitoring more than 1 million patients with more than 300 healthcare partners.

Investments and deals

Sustained R&D spending
Between 2018 and 2025 Withings reinvested 20 to 27% of annual revenue in R&D; it ran 31 clinical studies in 2025 and has 150 clinical articles published to date.
Government-funded AI risk scores
Risk scores were funded with a €10 million grant from the French government, and Withings has built an in-app AI agent that answers questions from the user's device data.
Biosency takeover
Withings recently took over Biosency, a Rennes company doing remote monitoring of respiratory insufficiency, notably for lung cancer patients.

Challenges and risks

Slow European adoption
Pivron says European health systems are slower than the US, pay providers on activity rather than outcomes and were not built for chronic conditions, so the business team spends effort educating the market.
Doctor-gated enrolment in the US
US remote monitoring adoption has been slow because a doctor must enrol each patient, which is why Withings is betting on the ACCESS model.
Reimbursement tied to proving outcomes
US payers invest when they can measure engagement, retention and outcomes, so Withings must keep producing retention data; it cites 97% retention at six months and 93% at 12 months for GLP-1 patients with its support.
Health culture in France
Carreel says the French have subcontracted their health to the medical world and wait until things go badly, leaving education to do before prevention products sell.

What leadership says

“The global healthcare conversation has shifted. Longevity, prevention, and at-home monitoring are no longer niche.”

Eric Carreel, Chairman and Co-founder · UK corporate press release on 2025 profitability, 6 May 2026

“Most of our uh best partners in the GLP1 space, they are not weight loss programs anymore. They are cardio metabolic health programs.”

Antoine Pivron, Vice President, Health Solutions · Healthcare IT Today video interview, 16 October 2026

“The challenge today is not technology. The technology already exists.”

Antoine Pivron, Vice President, Health Solutions · PharmaShots Q&A around HLTH Europe 2026, 19 June 2026

Where a supplier can help

Payer and pharma outcome reporting
Tied to the reimbursement challenge: tools or data services that help Withings show engagement, retention and outcomes to US payers and pharma partners.
Clinical and care-team operations
Tied to the ACCESS model priority: staffing, telehealth or workflow software for the Withings Medical care team that interacts with over-65 patients.
Market education in Europe
Tied to the slow European adoption challenge: medical marketing, provider education and market-access support for remote monitoring in European health systems.
Device logistics for B2B kits
Tied to the obesity and GLP-1 priority: fulfilment, cellular connectivity and kitting for Body Pro scales shipped to patients with the drug.
AI and data infrastructure for risk scores
Tied to the risk-score priority and the AI investment: data, model validation and clinical study support for new cardiometabolic scores.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Withings?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Withings

What does Withings do?

Withings makes medical-grade connected health devices such as smart scales, ECG watches and blood pressure monitors, and sells remote patient monitoring to health programs, hospitals, insurers and research organisations through its Health Solutions division.

Is Withings profitable?

Yes. Withings says it reached full-year profitability in 2025. It does not publish absolute revenue, but says global revenue grew approximately 90% since 2018.

How many employees does Withings have?

Withings cites a global team of 400.

Who leads Withings?

Eric Carreel, co-founder, who bought the company back from Nokia in 2018. Antoine Pivron leads the B2B Health Solutions division.

What is Withings' strategy?

To grow recurring Withings+ revenue and expand B2B remote monitoring around chronic conditions, led by obesity and GLP-1 programs and moving toward cardiometabolic risk scores.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)